Clazosentan + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage
Conditions
Aneurysmal Subarachnoid Hemorrhage
Trial Timeline
Feb 3, 2019 → Nov 18, 2022
NCT ID
NCT03585270About Clazosentan + Placebo
Clazosentan + Placebo is a phase 3 stage product being developed by Idorsia for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT03585270. Target conditions include Aneurysmal Subarachnoid Hemorrhage.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03585270 | Phase 3 | Completed |
| NCT00558311 | Phase 3 | Completed |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erythropoietin beta | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan | Idorsia | Phase 2 | 47 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 2 | 47 |
| GTX-104 + Nimodipine Capsules | Grace Therapeutics | Phase 1 | 25 |
| GTX-104 + Nimotop 30 MG Oral Capsule | Grace Therapeutics | Phase 3 | 69 |